Skip to main content
Divisions
Molecular diagnostics and distributed qPCR solutions.
Complete PCR solutions for molecular diagnostics.
Customised NGS for next-generation molecular insights.
Technologies
Instruments
Miniaturised qPCR devices with superior performance
Software Solutions
Cloud-based platform driven by artificial intelligence for advanced operations
Reagents
Deep multiplexing solutions and innovative reagents for all use cases
About us
Vision & Values
Our identity and the principles that guide the Group.
Numbers and Certifications
Reliability, performance and standards that define our work.
Leadership
The management team leading Helyx Industries.
About Helyx
The history, evolution and culture of our Group.
Insights
See all Insights
21 January 2026 | Vision & Strategy
Interview with the CEO - Innovation and the future of Helyx Industries
From the integration of Ulisse Biomed and Hyris to the rebranding that consolidated the Helyx identity and the new industrial structure with three complementary divisions (Hyris, Vytro, Mytho). Interview with Nicola Basile — CEO of Helyx Industries S.p.A.
22 December 2025 | Vision & Strategy
Helyx Industries: one group, three divisions. From distributed qPCR to tailor-made NGS
Helyx Industries was born out of a paradigm shift: from Ulisse Biomed to an integrated industrial group with three complementary divisions — Hyris, Vytro and Mytho — covering the entire spectrum of molecular diagnostics, from distributed qPCR to customised NGS. This article recounts the transformation, the new structure and the vision that now guides Helyx's evolution.
News
Updates and announcements
19 January 2026
Helyx Industries is born: a rebranding that consolidates a new three-division industrial structure
Press releases
26 December 2025
Comunicazione eventi societari 2026
Press releases
19 December 2025
Comunicazione di variazione del capitale sociale, deposito attestazione ai sensi dell'art. 2444 C.C. e statuto aggiornato
Press releases
12 December 2025
Efficacia del cambio di denominazione sociale da "Ulisse Biomed S.p.A." a "Helyx Industries S.p.A."
Investors
Helyx Industries is an industrial group active in the field of genetics. It has proprietary technologies and processes for complete and integrated solutions in molecular biology, from PCR to NGS. Through its divisions, it offers its solutions directly to diagnostic laboratories and hospitals or provides its services to diagnostic and industrial partners. Helyx Industries is listed on Euronext Growth in Milan.
Read more
Contact us
IT
EN
IT
EN
Divisions
Molecular diagnostics and distributed qPCR solutions.
Hyris System™
Agrifood & Nutraceuticals Catalogue
Development and OEM services
Complete PCR solutions for molecular diagnostics.
Human Health Catalogue
Customised NGS for next-generation molecular insights.
Customised NGS panels
Compatible areas & technologies
Technologies
Instruments
Miniaturised qPCR devices with superior performance
bCUBE™
bGATE™
Software Solutions
Cloud-based platform driven by artificial intelligence for advanced operations
bAPP™
Reagents
Deep multiplexing solutions and innovative reagents for all use cases
Sagitta™
Stable multiplex reagents
About Us
Vision & Values
Our identity and the principles that guide the Group.
Vision
Mission
Numbers and Certifications
Reliability, performance and standards that define our work.
Facts and Figures
Certifications
Leadership
The management team leading Helyx Industries.
People
About Helyx
The history, evolution and culture of our Group.
Our History
Timeline
Insights
News
Updates & announcements
Commercial news announced by Helyx Industries.
Read all
Press releases
Regulated and price-sensitive press releases.
Read all
Scientific Publications
Research, studies and published scientific papers.
Read all
Investors
Helyx Industries
Helyx Industries is an integrated biotech group with proprietary technologies that develops diagnostic solutions, focusing on public health, distributed diagnostics and molecular innovation.
Download Pitch Deck
Overview
Corporate Governance
Information for shareholders
Financial data
Press releases
Financial calendar
Shareholders' meeting
Analyst Coverage
Warrant
Internal dealing
Investment Agreement with GCF
Concluded extraordinary transactions
IPO
Investor Relations Contacts
Contacts
10 December, 2018
Updates and announcements
CONCESSION OF POR FESR 1.3.B (2017)
19 January 2026
Helyx Industries is born: a rebranding that consolidates a new three-division industrial structure
CONTINUE TO READING
07 August 2025
Papillomavirus Screening: Self-sampling with HPV-Selfy is Effective and Well-Accepted by Women, a New Study Confirms.
CONTINUE TO READING
06 August 2025
COMMUNICATION OF CONCESSION FOR POR FESR 2021-2027
CONTINUE TO READING
09 May 2025
Ulisse Biomed supports the fight against malaria
CONTINUE TO READING
14 April 2025
The innovative soul of Ulisse Biomed: the research and development that drives our future
CONTINUE TO READING
12 March 2025
Hyris expands testing rapid technology aimed at supporting the fight against malaria
CONTINUE TO READING
29 January 2025
New partnership agreement with Capebio
CONTINUE TO READING
20 January 2025
NEW DISTRIBUTION AGREEMENT WITH MONTEBELLO DIAGNOSTICS
CONTINUE TO READING
18 December 2024
A new brand identity for the Group
CONTINUE TO READING
09 December 2024
Microbiota: a market with high potential
CONTINUE TO READING
19 January 2026
Helyx Industries is born: a rebranding that consolidates a new three-division industrial structure
CONTINUE TO READING
07 August 2025
Papillomavirus Screening: Self-sampling with HPV-Selfy is Effective and Well-Accepted by Women, a New Study Confirms.
CONTINUE TO READING
06 August 2025
COMMUNICATION OF CONCESSION FOR POR FESR 2021-2027
CONTINUE TO READING
09 May 2025
Ulisse Biomed supports the fight against malaria
CONTINUE TO READING
14 April 2025
The innovative soul of Ulisse Biomed: the research and development that drives our future
CONTINUE TO READING
12 March 2025
Hyris expands testing rapid technology aimed at supporting the fight against malaria
CONTINUE TO READING
29 January 2025
New partnership agreement with Capebio
CONTINUE TO READING
20 January 2025
NEW DISTRIBUTION AGREEMENT WITH MONTEBELLO DIAGNOSTICS
CONTINUE TO READING
18 December 2024
A new brand identity for the Group
CONTINUE TO READING
09 December 2024
Microbiota: a market with high potential
CONTINUE TO READING
